SCHEMBL26631983

SCHEMBL26631983

O=C(OCCCCOCCO)c1ccccc1

nearest known ligand 0.76

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 2/20 0.76
LMNA P02545 1/20 0.56
ALDH1A1 P00352 1/20 0.51
MAPK1 P28482 2/20 0.49
HIF1A Q16665 1/20 0.49
SLC6A2 P23975 1/20 0.49
SLC6A3 Q01959 1/20 0.49
KMT2A Q03164 1/20 0.49
BCHE P06276 2/20 0.47
SCN1A P35498 1/20 0.47
SCN2A Q99250 1/20 0.47
SCN3A Q9NY46 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.46
ESR1 P03372 1/20 0.45
ESR2 Q92731 1/20 0.45
TP53 P04637 1/20 0.45
CYP3A4 P08684 1/20 0.45
TSHR P16473 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26189843 0.93 TDP1 (0.76) TDP1LMNAALDH1A1MAPK1HIF1A
SCHEMBL16041456 0.93 TDP1 (0.76) TDP1LMNAALDH1A1MAPK1HIF1A
SCHEMBL1674740 0.93 TDP1 (0.88) TDP1LMNAALDH1A1MAPK1HIF1A
SCHEMBL27911289 0.92 TDP1 (0.73) TDP1LMNAALDH1A1MAPK1HIF1A
SCHEMBL26189844 0.90 TDP1 (0.70) TDP1LMNAALDH1A1MAPK1HIF1A
SCHEMBL818564 0.89 TDP1 (0.63) TDP1LMNAALDH1A1MAPK1HIF1A
SCHEMBL9137591 0.89 TDP1 (0.63) TDP1LMNAALDH1A1MAPK1HIF1A
SCHEMBL2442856 0.89 TDP1 (0.63) TDP1LMNAALDH1A1MAPK1HIF1A
Ethylene Glycol SCHEMBL523532 0.89 TDP1 (0.88) TDP1LMNAALDH1A1MAPK1HIF1A
SCHEMBL115000 0.89 TDP1 (0.81) TDP1LMNAALDH1A1MAPK1HIF1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230357134-A1 AGENTS FOR USE IN THE TREATMENT OF AMYLOIDOSIS UCL BUSINESS LTD (GB) 2023-11-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230357134-A1 AGENTS FOR USE IN THE TREATMENT OF AMYLOIDOSIS TTR, C1R, APOB TDP1 3163/4885LMNA 63/4885ALDH1A1 1891/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.